Compare APT & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APT | CVM |
|---|---|---|
| Founded | 1983 | 1983 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.4M | 41.2M |
| IPO Year | 1995 | 1987 |
| Metric | APT | CVM |
|---|---|---|
| Price | $5.25 | $4.70 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 47.5K | ★ 77.8K |
| Earning Date | 03-11-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $59,096,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.71 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.06 | $1.98 |
| 52 Week High | $6.20 | $20.41 |
| Indicator | APT | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 56.49 | 38.64 |
| Support Level | $4.96 | $4.73 |
| Resistance Level | $5.64 | $5.49 |
| Average True Range (ATR) | 0.27 | 0.53 |
| MACD | 0.02 | -0.09 |
| Stochastic Oscillator | 40.58 | 1.45 |
Alpha Pro Tech Ltd is in the business of protecting people, products and environments. It is developing, manufacturing and marketing a line of disposable protective apparel and infection control products for the cleanroom, industrial, pharmaceutical, medical and dental markets. It also manufacture a line of building supply construction weatherization products that are sold under the Alpha Pro Tech brand name. The Company operates through two business segments: Building Supply and Disposable Protective Apparel. Key revenue is generated from Building Supply: consisting of a line of construction supply weatherization products. The construction supply weatherization products consist of housewrap and synthetic roof underlayment and synthetic roof underlayment accessories.
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.